Berktas Bahadir M, Koyuncu Adem
Am J Trop Med Hyg. 2022 Feb 25;106(4):1104-1107. doi: 10.4269/ajtmh.21-1010. Print 2022 Apr 6.
Severe cases of COVID-19 are being reported in patients with comorbidities and drug-induced immunosuppression. The risk seems to depend on the type of immunosuppressive agents used, and it is particularly high with rituximab because of its long-lasting effects. We report a 71-year-old man with COVID-19, mantle cell lymphoma, and rituximab-associated immunodeficiency. His COVID-19 clinical course was severe, unremitting, prolonged, and with frequent acute exacerbations requiring hospitalization. Viral shedding and failure to develop anti-severe acute respiratory syndrome coronavirus 2 antibodies continued for at least 6 months.
据报道，患有合并症和药物性免疫抑制的患者中出现了新冠肺炎重症病例。风险似乎取决于所使用的免疫抑制剂类型，由于利妥昔单抗的持久作用，使用该药物时风险尤其高。我们报告了一名71岁男性，患有新冠肺炎、套细胞淋巴瘤和利妥昔单抗相关免疫缺陷。他的新冠肺炎临床病程严重、持续、漫长，且频繁急性加重，需要住院治疗。病毒脱落以及未能产生抗严重急性呼吸综合征冠状病毒2抗体的情况持续了至少6个月。
